Form 4: Cytek Biosciences CTO Ming Yan Sells Shares Under 10b5-1 Trading Plan

Cytek Biosciences' Chief Technology Officer, Ming Yan, sold a total of 40,000 shares of common stock on March 18 and 19, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Ming Yan, the Chief Technology Officer of Cytek Biosciences, Inc., sold 20,000 shares of common stock on March 18, 2024, at a weighted average price of $6.77.
• The shares were sold in multiple transactions with prices ranging from $6.55 to $6.87.
• Following this transaction, Yan directly owns 6,030,402 shares of Cytek Biosciences.
• On March 19, 2024, Yan sold another 20,000 shares of common stock at a weighted average price of $6.71.
• These shares were sold in multiple transactions with prices ranging from $6.56 to $6.83.
• After the second transaction, Yan directly owns 6,010,402 shares of Cytek Biosciences.
• The sales were executed under a Rule 10b5-1 trading plan adopted on November 30, 2023.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating insider selling. The sales were conducted under a pre-arranged 10b5-1 trading plan, which mitigates potential negative sentiment. Overall, the sentiment is neutral.

Industry Context

Insider selling can sometimes be interpreted negatively by the market, but sales under a pre-arranged 10b5-1 trading plan are generally viewed as less concerning since they are planned in advance and not based on current insider information. It is common for executives to use these plans for diversification or liquidity purposes.

Stakeholder Impact

• The sale of shares by a key executive could potentially create uncertainty among shareholders, although the existence of a 10b5-1 plan may alleviate concerns.

Key Dates